Overview

Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma

Status:
Terminated
Trial end date:
2011-06-06
Target enrollment:
Participant gender:
Summary
To evaluate and compare the expression and change in expression of key severe asthma targets at baseline in mile to moderate asthmatics vs. severe asthmatic subjects. To evaluate and compare the airway pathology at baseline and changes in airway pathology in relation to asthma severity.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate